Veraxa Biotech Reports First In Vivo Proof-of-Concept for BiTAC-ADC Platform
VRXA sits 18% above its 52-week low of $1.04.
Summary
Veraxa Biotech reported first in vivo proof-of-concept for its BiTAC-ADC platform, showing strong tumor regression at a single 3 mg/kg dose in a xenograft breast cancer model with no body weight decrease. This is the first in vivo validation of the platform, following earlier in vitro results and patent filings. The data support the platform's potential for improved safety and efficacy in solid tumors, though it remains preclinical. The company has an active $50M ATM program and recently appointed a new CFO, providing context for ongoing development.
At the time of this announcement, VRXA was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $168.4M. The 52-week trading range was $1.04 to $27.36. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.